CN1985864A - 一种主要由甘草酸或其盐、人参和灵芝制成的药物组合物 - Google Patents
一种主要由甘草酸或其盐、人参和灵芝制成的药物组合物 Download PDFInfo
- Publication number
- CN1985864A CN1985864A CN 200510045376 CN200510045376A CN1985864A CN 1985864 A CN1985864 A CN 1985864A CN 200510045376 CN200510045376 CN 200510045376 CN 200510045376 A CN200510045376 A CN 200510045376A CN 1985864 A CN1985864 A CN 1985864A
- Authority
- CN
- China
- Prior art keywords
- parts
- ginseng
- radix
- group
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000208340 Araliaceae Species 0.000 title claims abstract description 229
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 229
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 228
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 228
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 241000222336 Ganoderma Species 0.000 title claims abstract description 41
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 title claims abstract description 37
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 239000001685 glycyrrhizic acid Substances 0.000 title claims abstract description 37
- 229960004949 glycyrrhizic acid Drugs 0.000 title claims abstract description 37
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 235000019410 glycyrrhizin Nutrition 0.000 title claims abstract description 37
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 title claims abstract description 37
- 150000003839 salts Chemical class 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title claims description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 55
- 239000000284 extract Substances 0.000 claims abstract description 37
- 150000004676 glycans Chemical class 0.000 claims description 86
- 150000007949 saponins Chemical class 0.000 claims description 84
- 235000017709 saponins Nutrition 0.000 claims description 75
- 229920001282 polysaccharide Polymers 0.000 claims description 74
- 239000005017 polysaccharide Substances 0.000 claims description 74
- 229930182490 saponin Natural products 0.000 claims description 70
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 claims description 64
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 229930182494 ginsenoside Natural products 0.000 claims description 22
- 229940089161 ginsenoside Drugs 0.000 claims description 22
- 239000004615 ingredient Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 10
- 239000000890 drug combination Substances 0.000 claims description 5
- 238000007670 refining Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 37
- 208000006454 hepatitis Diseases 0.000 abstract description 21
- 238000005516 engineering process Methods 0.000 abstract description 17
- 231100000283 hepatitis Toxicity 0.000 abstract description 12
- 230000002195 synergetic effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 127
- 238000002347 injection Methods 0.000 description 93
- 239000007924 injection Substances 0.000 description 93
- 241000207961 Sesamum Species 0.000 description 91
- 235000003434 Sesamum indicum Nutrition 0.000 description 91
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 82
- 239000000243 solution Substances 0.000 description 60
- 239000002131 composite material Substances 0.000 description 55
- 229960004756 ethanol Drugs 0.000 description 33
- 239000000706 filtrate Substances 0.000 description 31
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 28
- 235000002639 sodium chloride Nutrition 0.000 description 28
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 26
- 239000008215 water for injection Substances 0.000 description 26
- 210000004185 liver Anatomy 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 229920001214 Polysorbate 60 Polymers 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 235000009508 confectionery Nutrition 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 206010019668 Hepatic fibrosis Diseases 0.000 description 15
- 239000008187 granular material Substances 0.000 description 15
- 239000013558 reference substance Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 239000004471 Glycine Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 150000004804 polysaccharides Polymers 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 235000001727 glucose Nutrition 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 238000004064 recycling Methods 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 10
- 239000008108 microcrystalline cellulose Substances 0.000 description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- 208000005374 Poisoning Diseases 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 238000007689 inspection Methods 0.000 description 9
- 231100000572 poisoning Toxicity 0.000 description 9
- 230000000607 poisoning effect Effects 0.000 description 9
- 238000004321 preservation Methods 0.000 description 9
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 229960001305 cysteine hydrochloride Drugs 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 239000012567 medical material Substances 0.000 description 7
- 239000011265 semifinished product Substances 0.000 description 7
- 238000001694 spray drying Methods 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 230000001476 alcoholic effect Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 231100000753 hepatic injury Toxicity 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- -1 ucleosides Chemical class 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 241000272525 Anas platyrhynchos Species 0.000 description 5
- 206010008909 Chronic Hepatitis Diseases 0.000 description 5
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 241000725618 Duck hepatitis B virus Species 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000008227 sterile water for injection Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 231100000111 LD50 Toxicity 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000005262 decarbonization Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000009287 sand filtration Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000013505 freshwater Substances 0.000 description 3
- 235000020710 ginseng extract Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- RSJOBNMOMQFPKQ-ZVGUSBNCSA-L copper;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Cu+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O RSJOBNMOMQFPKQ-ZVGUSBNCSA-L 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 206010019847 hepatosplenomegaly Diseases 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 125000001477 organic nitrogen group Chemical group 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 description 1
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- LMYVDPWHMJXPIY-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanol Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCO LMYVDPWHMJXPIY-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 241000272522 Anas Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241001489091 Ganoderma sinense Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- YEZWWUMWIFKEQM-UHFFFAOYSA-N O.OC.ClC(Cl)Cl.CCOC(C)=O Chemical compound O.OC.ClC(Cl)Cl.CCOC(C)=O YEZWWUMWIFKEQM-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 229920001231 Polysaccharide peptide Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 重量配比 | 给药剂量(mg/kg) | ALT(n mol/s.L) | AST(n mol/s.L) |
空白对照组模型组甘草酸二铵组人参多糖组人参总皂苷组灵芝多糖组 | ------ | -2030303030 | 230.56±20.76389.24±83.34**309.43±36.68*#325.84±42.43*#321.34±40.68*#339.46±39.67*# | 221.78±31.39393.59±48.57**326.54±33.36u346.72±37.56*#343.58±36.45*#350.43±37.64*# |
甘参芝组合物注射液I组(甘草酸二铵+人参多糖+灵芝多糖) | 10mg+5mg+30mg20mg+5mg+40mg50mg+50mg+50mg100mg+10mg+60mg150mg+10mg+60mg200mg+10mg+60mg250mg+15mg+100mg300mg+15mg+150mg400mg+20mg+200mg | 303030303030303030 | 276.38±29.48##&★△273.64±28.87##&★△266.81±25.93##&★△262.53±24.72##&★△252.34±21.56##&★△256.35±22.46##&★△261.66±24.39##&★△269.68±26.15##&★△275.55±28.99##&★△ | 286.48±29.57##&★△282.67±29.26##&★△276.46±26.37##&★△261.63±23.38##&★△246.06±20.22##&★△252.69±21.67##&★△263.64±24.85##&★△270.48±26.94##&★△279.18±27.82##&★△ |
甘参芝组合物注射液II组(甘草酸二铵+人参总皂苷+灵芝多糖) | 10mg+20mg+30mg20mg+20mg+40mg50mg+30mg+50mg100mg+40mg+60mg150mg+40mg+60mg200mg+50mg+60mg250mg+50mg+100mg300mg+60mg+150mg400mg+80mg+200mg | 303030303030303030 | 275.84±31.38##&◆△269.35±28.51##&◆△262.76±26.57##&◆△257.56±24.31##&◆△250.52±20.76##&◆△254.24±23.15##&◆△260.58±25.64##&◆△272.81±27.64##&◆△276.58±29.86##&◆△ | 293.53±30.36##&◆△284.53±28.67##&◆△278.62±27.35##&◆△269.46±25.88##&◆△253.14±22.61##&◆△259.63±23.26##&◆△265.76±25.43##&◆△275.59±27.49##&◆△286.48±30.64##&◆△ |
组别 | 动物数(只) | 给药剂量(mg/kg) | 肝指数(g/100g) | 脾指数(g/100g) |
空白对照组CCl4模型组甘草酸单铵组人参多糖组人参总皂苷组甘参芝组合物注射液I组(低剂量)甘参芝组合物注射液I组(中剂量)甘参芝组合物注射液I组(高剂量)甘参芝组合物注射液II组(低剂量)甘参芝组合物注射液II组(中剂量)甘参芝组合物注射液II组(高剂量) | 1010101010101010101010 | -10202020101520101520 | 6.318±1.0168.163±0.648**7.164±0.728*#7.298±0.759*#7.265±0.746*#6.726±0.738##&★6.635±0.749##&★6.404±0.823##&★6.802±0.726##&△6.684±0.753##&△6.396±0.845##&△ | 0.628±0.1180.744±0.063**0.664±0.047*#0.681±0.061*#0.692±0.065*#0.649±0.076##&★0.637±0.082##&★0.630±0.086##&★0.646±0.073##&△0.638±0.085##&△0.632±0.088##&△ |
组别 | 给药剂量(mg/kg) | 治疗前DHBV-DNA滴度 | 治疗后7dDHBV-DNA滴度 | 治疗后14dDHBV-DNA滴度 | 停药后3dDHBV-DNA滴度 |
空白对照组阳性对照组甘草酸二铵组人参多糖组人参总皂苷组甘参芝组合物注射液I组(低剂量)甘参芝组合物注射液I组(中剂量)甘参芝组合物注射液I组(高剂量)甘参芝组合物注射液II组(低剂量)片参芝组合物注射液II组(中剂量)甘参芝组合物注射液II组(高剂量) | -50303030102030102030 | 1.58±0.051.61±0.031.56±0.051.59±0.021.60±0.031.55±0.041.60±0.041.58±0.031.56±0.051.59±0.041.60±0.03 | 1.59±0.060.86±0.15**&&1.26±0.07*&1.31±0.06*&1.32±0.05*&1.02±0.12**&&#★0.93±0.15**&&#★0.82±0.16**&&#★1.00±0.13**&&#△0.95±0.14**&&#△0.85±0.15**&&#△ | 1.59±0.040.81±0.17**&&1.23 ±0.08*&1.28±0.07*&1.27±0.07*&0.95±0.13**&&#★0.88±0.14**&&#★0.80±0.18**&&#★0.96±0.13**&&#△0.92±0.15**&&#△0.82±0.16**&&#△ | 1.57±0.041.59±0.041.39±0.05*&1.36±0.06*&1.38±0.05*&1.05±0.10**&&#★0.98±0.11**&&#★0.86±0.15**&&#★1.03±0.11**&&#△0.95±0.13**&&#△0.89±0.15**&&#△ |
组别 | 给药剂量(mg/kg) | ALT/U·L-1 | AST/U·L-1 | TP/g·L-1 | Alb/g·L-1 | A/G |
空白对照组模型组甘草酸二铵组人参多糖组人参总皂苷组甘参芝组合物注射液I组(低剂量)甘参芝组合物注射液I组(中剂量)甘参芝组合物注射液I组(高剂量)甘参芝组合物注射液II组(低剂量)甘参芝组合物注射液II组(中剂量)甘参芝组合物注射液II组(高剂量) | 1010303030102030102030 | 54.0±12.6110.1±15.8**79.6±13.9*#83.4±12.8*#81.5±13.6*#65.8±9.2##&★62.4±8.9##&★58.6±8.5##&★64.6±9.6##&△59.9±9.5##&△56.5±9.4##&△ | 82.2±16.0105.8±12.5**91.8±1 5.7*#91.6±1 5.9*#91.3±15.5*#85.5±1 5.8##&★84.3±16.1##&★81.6±17.5##&★85.7±15.9##&△83.1±15.8##&△82.7±16.3##&△ | 51.4±5.885.6±9.8**70.4±8.7*#72.5±9.1*#71.8±8.9*#63.8±7.3##&★60.5±6.8##&★55.1±6.3##&★64.0±7.6##&△58.6±6.6##&△54.9±6.4##&△ | 24.9±2.715.9±3.1**19.6±2.2*#18.8±2.3*#19.8±2.0*#21.6±2.3##&★22.5±2.5##&★23.6±2.8##&★21.5±2.2##&△22.8±2.4##&△23.4±2.7##&△ | 0.94±0.420.23±0.09**0.38±0.16*#0.35±0.13*#0.38±0.15*#0.51±0.29##&★0.59±0.34##&★0.75±0.39##&★0.51±0.31##&△0.64±0.35##&△0.74±0.37##&△ |
批号 | 人参多糖含量(%) | 得率(%) |
1 | 83.36 | 0.98 |
2 | 88.42 | 1.13 |
3 | 92.51 | 1.33 |
平均 | 88.10 | 1.14 |
批号 | 人参总皂苷含量(%) | 人参皂苷Re、人参皂苷Rg1含量(%) | 得率(%) |
1 | 72.06 | 41.03 | 1.10 |
2 | 68.24 | 39.85 | 1.08 |
3 | 65.98 | 37.81 | 1.03 |
平均 | 68.76 | 39.56 | 1.07 |
批号 | 多糖含量(%) | 得率(%) |
1 | 63.64 | 1.96 |
2 | 61.05 | 1.63 |
3 | 53.21 | 1.24 |
平均 | 59.30 | 1.61 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510045376A CN1985864B (zh) | 2005-12-19 | 2005-12-19 | 一种主要由甘草酸或其盐、人参和灵芝制成的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510045376A CN1985864B (zh) | 2005-12-19 | 2005-12-19 | 一种主要由甘草酸或其盐、人参和灵芝制成的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1985864A true CN1985864A (zh) | 2007-06-27 |
CN1985864B CN1985864B (zh) | 2010-05-12 |
Family
ID=38182891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200510045376A Expired - Fee Related CN1985864B (zh) | 2005-12-19 | 2005-12-19 | 一种主要由甘草酸或其盐、人参和灵芝制成的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1985864B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102617893A (zh) * | 2012-04-06 | 2012-08-01 | 吉林省宏久生物科技股份有限公司 | 人参皂甙Rg3、多糖及灵芝多糖的组合物制备及其应用 |
CN103005595A (zh) * | 2012-12-20 | 2013-04-03 | 段海庆 | 一种饮料 |
CN103005594A (zh) * | 2012-12-18 | 2013-04-03 | 段海庆 | 一种饮料 |
CN103223016A (zh) * | 2013-05-06 | 2013-07-31 | 赵全成 | 一种防治糖尿病的人参桑菊组合物 |
CN108992498A (zh) * | 2018-09-27 | 2018-12-14 | 河南红丽桦医药科技有限公司 | 一种天然中药护肝茶及其制备方法 |
CN110302244A (zh) * | 2019-08-19 | 2019-10-08 | 杭州荣泽生物科技有限公司 | 一种黄芪多糖联合间充质干细胞在制备治疗晚期肝硬化药物中的应用 |
CN110495604A (zh) * | 2018-05-17 | 2019-11-26 | 山东禾桦生物科技有限公司 | 植物素组成物及其制造方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1194864A (zh) * | 1998-01-21 | 1998-10-07 | 唐书林 | 益肝代用茶 |
-
2005
- 2005-12-19 CN CN200510045376A patent/CN1985864B/zh not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102617893A (zh) * | 2012-04-06 | 2012-08-01 | 吉林省宏久生物科技股份有限公司 | 人参皂甙Rg3、多糖及灵芝多糖的组合物制备及其应用 |
CN103005594A (zh) * | 2012-12-18 | 2013-04-03 | 段海庆 | 一种饮料 |
CN103005594B (zh) * | 2012-12-18 | 2014-07-16 | 段海庆 | 一种饮料 |
CN103005595A (zh) * | 2012-12-20 | 2013-04-03 | 段海庆 | 一种饮料 |
CN103223016A (zh) * | 2013-05-06 | 2013-07-31 | 赵全成 | 一种防治糖尿病的人参桑菊组合物 |
CN110495604A (zh) * | 2018-05-17 | 2019-11-26 | 山东禾桦生物科技有限公司 | 植物素组成物及其制造方法 |
CN108992498A (zh) * | 2018-09-27 | 2018-12-14 | 河南红丽桦医药科技有限公司 | 一种天然中药护肝茶及其制备方法 |
CN110302244A (zh) * | 2019-08-19 | 2019-10-08 | 杭州荣泽生物科技有限公司 | 一种黄芪多糖联合间充质干细胞在制备治疗晚期肝硬化药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1985864B (zh) | 2010-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1985864B (zh) | 一种主要由甘草酸或其盐、人参和灵芝制成的药物组合物 | |
CN100584348C (zh) | 一种抗肝炎的药物组合物 | |
CN100574768C (zh) | 一种抗癌药物组合物及其制备方法和用途 | |
CN1977885B (zh) | 一种抗肝炎药物组合物 | |
CN1985873B (zh) | 甘草酸或其盐、人参和黄芪的药物组合物 | |
CN1985927A (zh) | 一种主要用于肝脏疾病的药物组合物 | |
CN1961898B (zh) | 一种复方半枝莲抗肿瘤药物组合物及其制备方法 | |
CN100534493C (zh) | 一种新的抗肿瘤复方药物 | |
CN101011543B (zh) | 一种新的抗肿瘤药物组合物 | |
CN1977886B (zh) | 一种由苦参素、灵芝和黄芪制成的药物组合物 | |
CN1954838B (zh) | 一种抗肿瘤的药物组合物 | |
CN100493522C (zh) | 一种苦参素和多糖的药物组合物 | |
CN1954839B (zh) | 由通关藤、人参和黄芪制成的药物组合物 | |
CN1970001B (zh) | 一种苦参素、五味子和人参配伍的治疗肝炎的药物组合物 | |
CN1977888B (zh) | 一种由黄芩苷、灵芝和丹参制成的药物组合物 | |
CN101073611B (zh) | 一种抗肿瘤的药物组合物 | |
CN1961894B (zh) | 一种新的复方药物组合物及其制备方法和用途 | |
CN1969922B (zh) | 一种复方药物组合物及其制备方法 | |
CN1961895B (zh) | 一种新的抗癌药物组合物及其制备方法 | |
CN1954845B (zh) | 一种肿节风复方药物组合物及其制备方法 | |
CN1985987B (zh) | 甘草酸或其盐和还原型谷胱甘肽的药物组合物 | |
CN101049336B (zh) | 一种抗癌药物组合物 | |
CN100574764C (zh) | 一种抗肝炎药物组合物及其制备方法 | |
CN1977887B (zh) | 一种用于治疗肝炎的药物组合物 | |
CN1969937A (zh) | 一种治疗肝炎的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: XUAN ZHU SHANDONG MEDICINE TECHNOLOGY CO. Free format text: FORMER OWNER: HUANG ZHENHUA Effective date: 20080530 |
|
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080530 Address after: Tianchen Avenue Ji'nan High-tech Development Zone in Shandong province No. 2518 post encoding: 250101 Applicant after: XUANZHU PHARMA Co.,Ltd. Address before: Post encoding No. 2518 block A, Tianchen Avenue Ji'nan High-tech Development Zone in Shandong Province: 250101 Applicant before: Huang Zhenhua |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAIAN SUSHI TECHNOLOGY TRANSFORMATION CENTER CO., Free format text: FORMER OWNER: SHANDONG XUANZHU MEDICAL TECHNOLOGY CO., LTD. Effective date: 20131008 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 226601 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131008 Address after: 226601 No. 8 Yingbin Road, software park, Haian County, Jiangsu Province Patentee after: Haian Su Fu Technology Transfer Center Co.,Ltd. Address before: Tianchen Avenue in Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 Patentee before: XUANZHU PHARMA Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100512 Termination date: 20161219 |
|
CF01 | Termination of patent right due to non-payment of annual fee |